Timeline
Last
$81.99
-0.08 (-0.10%)
24HR-0.1%
1W-1.9%
1M+5.5%
1Y+83.0%
Valuation
- Market Cap
- $16.1B
- Enterprise Value
- $17.6B
- P/E (TTM)
- —
- Forward P/E
- 141.33x
- Price / Sales
- 27.69x
- EV / EBITDA
- -35.32x
Cash Flow
- Operating Cash Flow
- -$444M
- Free Cash Flow
- -$317.9M
- FCF Margin
- -54.8%
- Cash Conversion
- 71.6%
- Cash / Share
- $4.8
Margins & Growth
- Gross Margin
- 95.1%
- Operating Margin
- -54.5%
- EBITDA Margin
- -86.0%
- Net Margin
- -124.4%
- Revenue Growth
- 66.8%
- Earnings Growth
- —
Balance Sheet
- Total Cash
- $940.2M
- Total Debt
- $2.5B
- Net Cash
- -$1.6B
- Debt / Equity
- —
- Current Ratio
- 1.52x
- Quick Ratio
- 1.40x
Returns & Ownership
- Return on Assets
- -28.0%
- Return on Equity
- —
- Dividend Yield
- —
- Payout Ratio
- 0.0%
- Beta
- 0.98
- Institutional Ownership
- 102.0%
Latest EPS-$0.84-0.4% surprise
Beat rate25%4 prints
Avg surprise-0.3%vs consensus
Next printAug 10, 2026EPS -$0.58
Quarterly EPS vs consensus
4 quarters Actual ConsensusLabels: beat $ · YoY %Revisions 7 up / 4 down
Earnings transcripts
Read management commentary and analyst Q&A.
No transcript dates are available yet for this ticker.
Forward estimates
Consensus expectations and estimate momentum.
PeriodEPSRevenueGrowth
0QJun 2026
-$0.58$219.7M+38.7%+1QSep 2026
-$0.49$251.8M+31.5%0YDec 2026
-$2.19$960.7M+42.2%+1YDec 2027
$0.58$1.6B+126.5%Primary research
Recent company filings
Jump directly to earnings releases, quarterly reports, and material updates.
8-KCorporate Changes & Voting Matters2026-07-228-KCorporate Changes & Voting Matters2026-07-028-KCorporate Changes & Voting Matters2026-06-268-KCorporate Changes & Voting Matters2026-05-278-KCorporate Changes & Voting Matters2026-05-1310-QPeriodic Financial Reports2026-05-078-KCorporate Changes & Voting Matters2026-03-3010-KPeriodic Financial Reports2026-02-248-KCorporate Changes & Voting Matters2026-02-128-KCorporate Changes & Voting Matters2026-01-218-KCorporate Changes & Voting Matters2026-01-128-KCorporate Changes & Voting Matters2025-10-29
BBIO stock research · BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate fo…
| Last price | $82 |
|---|---|
| Day change | -0.08 (-0.10%) |
| Market cap | $16.1B |
| P/E (TTM) | — |
| Sector | Healthcare |
| Industry | Biotechnology |